Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.National Institute for Health and Clinical Excellence (NICE) has issued final recommendation for GlaxoSmithKline's (GSK) Prolia (denosumab), for the treatment of post-menopausal osteoporotic fractures.
Subscribe to our email newsletter
Amgen and GlaxoSmithKline, who are co-marketing Prolia (denosumab), welcomed the NICE decision.
GSK said that the guidance recommends denosumab as a treatment option for the prevention of osteoporotic fragility fractures in postmenopausal women who are at risk and for whom oral bisphosphonates are unsuitable.
Denosumab has been designed to mimic the natural processes that control the breakdown of bone, thereby reducing the risk of future fractures.
Crawley GP Alun Cooper said that he was delighted that NICE has made the decision to give patients access to the convenient and effective treatment option.
"Denosumab is a treatment that prevents osteoporotic fractures, which could significantly reduce the financial burden of fragility fractures on the NHS as well as offering an alternative treatment option to patients for whom oral bisphosphonates are unsuitable," Cooper said.
Amgen general manager John Kearney said that they were delighted that the NICE appraisal of denosumab has resulted in this positive guidance.
"Amgen researchers were the first to discover a fundamental biochemical pathway that controls bone remodelling almost 15 years ago and we are thrilled that this discovery has led today to patients having access on the NHS to a convenient treatment that really has been shown to be highly effective in preventing fractures caused by osteoporosis," Kearney said.
GSK medical director Pim Kon said that the company is delighted at the news that denosumab has been approved for use on the NHS.